AbbVie : New Head-to-Head Phase 3 Data Show SKYRIZI Superior to Cosentyx across Primary and All Ranked Secondary Endpoints in Adults

NORTH CHICAGO - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx in a head-to-head Phase 3 study.1

SKYRIZI showed significantly higher rates of skin clearance compared to Cosentyx, meeting the primary endpoint of superiority with at least a 90 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52.1 Of patients treated with SKYRIZI, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks (p

(C) 2020 Electronic News Publishing, source ENP Newswire